Rocket Pharmaceuticals (RCKT) Consolidated Net Income (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Consolidated Net Income of -$48.8 million for Q1 2026, down 11.61% sequentially from -$43.7 million in Q4 2025, and up 23.14% YoY from -$39.6 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Consolidated Net Income (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Consolidated Net Income for 13 years, with the latest figure at -$48.8 million in Q1 2026.
- Quarterly Consolidated Net Income rose 23.14% year-over-year to -$48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$310.0 million (down 16.75% YoY) and the FY2025 annual result came in at -$361.6 million, up 8.22% from the prior year.
- Consolidated Net Income declined to -$48.8 million in Q1 2026 per RCKT's latest filing, from -$43.7 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$43.7 million in Q4 2025 and troughed at -$190.8 million in Q3 2023.
- A 5-year average of -$100.4 million and a median of -$71.9 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income surged 67.35% in 2022, then tumbled 64.86% in 2025.
- Over 5 years, Consolidated Net Income stood at -$68.3 million in 2022, then gained by 7.86% to -$62.9 million in 2023, then gained by 2.2% to -$61.6 million in 2024, then gained by 28.93% to -$43.7 million in 2025, then declined by 11.61% to -$48.8 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$48.8 million, -$43.7 million, and -$98.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | 123.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123.21 Mn |
| Mar 31, 2026 | -48.82 Mn |
| Dec 31, 2025 | -43.75 Mn |
| Sep 30, 2025 | -98.92 Mn |
| Jun 30, 2025 | -118.51 Mn |
| Mar 31, 2025 | -63.52 Mn |
| Dec 31, 2024 | -61.55 Mn |
| Sep 30, 2024 | -68.57 Mn |
| Jun 30, 2024 | -71.89 Mn |
| Mar 31, 2024 | -64.82 Mn |
| Dec 31, 2023 | -62.94 Mn |
| Sep 30, 2023 | -190.83 Mn |
| Jun 30, 2023 | -188.38 Mn |
| Mar 31, 2023 | -157.55 Mn |
| Dec 31, 2022 | -68.30 Mn |
| Sep 30, 2022 | -145.59 Mn |
| Jun 30, 2022 | -126.26 Mn |
| Mar 31, 2022 | -126.90 Mn |
| Dec 31, 2021 | -43.95 Mn |
| Sep 30, 2021 | -252.62 Mn |